It is a reflection of the very significant potential of Evgen Pharma’s technology that the company has been able to attract a high calibre commercial, scientific and advisory team.
Directors and Senior Management
Barry Clare, Non-Executive Chairman
Barry has over 20 years’ experience in the healthcare industry. He was a former main board director of the Boots Company plc and Chairman of University Hospital South Manchester (UHSM) Foundation Trust. As the former Managing Director of Boots Healthcare International, he led the global expansion of a leading portfolio of brands including Nurofen, Strepsils and Clearasil. Since leaving Boots, he has set up his own company, Clarat Partners LLP, and engineered several private equity backed transactions.
Dr Stephen Franklin, Chief Executive Officer
Stephen founded Evgen Pharma in 2007 and has over 20 years’ experience in the life science industries, focusing on the commercialisation of new technology. He was formally the CEO of Provexis plc (a spin-out from ANGLE plc), leading it from seed investment through to, and beyond, its admission to AIM in 2005. Stephen has a BSc in Biology (York), a PhD in Applied Biochemistry (Nottingham) and an MBA with distinction (Nottingham). He is a Fellow of the Royal Society of Medicine and an alumni of the Royal Commission for the Exhibition of 1851.
Richard Moulson, Chief Financial Officer
Richard is a qualified chartered accountant with over 20 years’ post-qualification experience working as a chief financial officer for UK quoted and private equity and venture capital owned companies. Richard trained with Coopers & Lybrand and spent 10 years with Deutsche Morgan Grenfell in corporate finance working on fundraisings, IPOs and M&A transactions in the UK and internationally. He has considerable life science experience in companies including Intercytex Group Plc, ReNeuron Group plc and Cobra Therapeutics.
Dr Alan Barge, Non-Executive Director
Alan is the former chief medical officer of Singapore-based ASLAN Pharmaceuticals PTE. Up until 2011, he was vice-president and head of oncology & infection at AstraZeneca, a role in which he was responsible for the overall strategy in oncology and infection from drug discovery to proof-of-concept. He was also chairman of AstraZeneca’s Therapy Area Portfolio Team and accountable for the design and delivery of all projects, including budgetary oversight. Prior to his career at AstraZeneca, Alan was European and global medical director for Amgen Inc.
Dr Susan Foden, Non-Executive Director
Susan has broad experience in executive and non-executive roles at both public and private companies and at funding organisations. Her current directorships include Vectura plc and BTG plc and she was the former Chair at BerGenBio AS. She is a former investor director with Merlin Biosciences and, from 1987 to 2000, was chief executive officer of the technology transfer company Cancer Research Campaign Technology Limited. She studied biochemistry at the University of Oxford, obtaining an MA and a DPhil.
Susan Clement-Davies, Non-Executive Director
Susan is an experienced financier with over 25 years of capital markets and investment banking experience, including 10 years at Citigroup as Managing Director of Equity Capital Markets and most recently as Managing Director of Torreya, an investment bank solely focused on life sciences. Susan has a BSc in Economics from University College London and a MSc in Economics from London School of Economics.
Sally Ross, Clinical Development Officer
Sally has over 18 years of experience working across pre-clinical and clinical settings in academia, pharma and CROs. Sally held many different roles at AstraZeneca, starting off as a translational Scientist working on Iressa and then moved into more clinical roles as a Global Project/Programme Manager in the Oncology and Infection Therapeutic Areas, and subsequently as a Principal Medical Scientist in both early and late clinical development. Upon leaving AstraZeneca Sally worked for a large mid-sized contract research organisation as Director of Project Management.
Dr Thomas Morris – Medical Advisor
Tom is a physician who has worked in pharmaceutical medicine and drug development for over 20 years with much of this time specialising in oncology. After several years working in clinical medicine, he joined firstly Medeval Ltd (University of Manchester) and then AstraZeneca, where he has held a number of global R&D roles. Most recently these included Senior Medical Director and Executive Director Clinical Programs. He has overseen several global drug development programs, interacting with leading external medical and scientific experts, academic groups and regulatory agencies.
Liz Jenkins – Regulatory Affairs
Liz Jenkins is a specialist in International Regulatory Affairs with over 30 years’ experience in the biopharmaceutical sector. She started her career at the East Birmingham and Royal Free Hospitals before joining Celltech Ltd (now UCB Celltech) in 1983 and the Amgen in 1993. Since 1998 Liz has operated as both an independent or affiliated consultant offering strategic advice and practical assistance in the areas of drug development, clinical trials, regulatory affairs and product licensing to more than 50 different biopharmaceutical companies.
Professor Albena Dinkova-Kostova – Independent Scientific Advisor
Albena is a Professor of Chemical Biology at the Jacqui Wood Cancer Centre, Division of Cellular Medicine, University of Dundee School of Medicine. She obtained her PhD degree in Biochemistry and Biophysics from Washington State University and then joined the research group of Professor Paul Talalay, who discovered the anti-cancer effect of sulforaphane at Johns Hopkins University back in 1992. She has a core research interest in oxidative stress and inflammation and has published over 100 research papers including many on sulforaphane as an activator of the Nrf2 pathway and as a potential therapeutic strategy for protection against chronic degenerative diseases.
Professor Giovanni Mann – Independent Scientific Advisor
Giovanni has been Professor of Vascular Physiology at King’s College London since 1997 and obtained his PhD in Physiology from University College London in 1978. His core research interest is in the signalling cascades involved the transcriptional activation of antioxidant defence genes and their role in diseases such as ischaemic stroke, atherosclerosis and gestational diabetes. He has a particular interest in sulforaphane as an activator of Nrf2 targeted antioxidant enzymes and the importance of this pathway in ischaemia-reperfusion injury in brain endothelial cells. He has published over 160 research papers and coordinated over 36 research symposia at international conferences.